Free Trial

Chardan Capital Issues Pessimistic Forecast for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

EyePoint Pharmaceuticals logo with Medical background

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) had its price objective cut by equities researchers at Chardan Capital from $33.00 to $27.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Chardan Capital's price objective suggests a potential upside of 356.08% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $25.29.

Read Our Latest Report on EYPT

EyePoint Pharmaceuticals Price Performance

EYPT stock traded up $0.07 during midday trading on Thursday, hitting $5.92. 276,966 shares of the stock traded hands, compared to its average volume of 821,098. The firm has a market cap of $407.36 million, a P/E ratio of -2.96 and a beta of 1.58. The stock's fifty day simple moving average is $6.01 and its 200-day simple moving average is $7.46. EyePoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The firm had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. On average, research analysts predict that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Institutional Trading of EyePoint Pharmaceuticals

A number of large investors have recently bought and sold shares of EYPT. Barclays PLC boosted its holdings in EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after acquiring an additional 197,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in EyePoint Pharmaceuticals by 1,171.3% in the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after acquiring an additional 342,516 shares during the last quarter. Franklin Resources Inc. boosted its holdings in EyePoint Pharmaceuticals by 9.9% in the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after acquiring an additional 362,399 shares during the last quarter. abrdn plc bought a new position in EyePoint Pharmaceuticals during the fourth quarter worth about $1,719,000. Finally, Rhumbline Advisers boosted its holdings in EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock worth $667,000 after buying an additional 12,443 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

EyePoint Pharmaceuticals Company Profile

(Get Free Report)

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Recommended Stories

Analyst Recommendations for EyePoint Pharmaceuticals (NASDAQ:EYPT)

Should You Invest $1,000 in EyePoint Pharmaceuticals Right Now?

Before you consider EyePoint Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.

While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines